Trips, Access to Medicines and Developing Nations: Towards an Open Source Solution

21 Pages Posted: 19 Dec 2006

See all articles by Krishna Ravi Srinivas

Krishna Ravi Srinivas

Research Information System for Developing Countries (RIS)

Multiple version iconThere are 2 versions of this paper

Date Written: November 2006


The access to drugs and development of new drugs to what are called as neglected diseases in developing nations is a major issue. To what extent intellectual property rights (IPRS) facilitate or hinder this is a controversial issue. The harmonization of global IP regime under TRIPS norms has eliminated many of the options including using process patents without limits, which were earlier available to developing nations. A report of the WHO Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH) has pointed out the problems and has suggested some solutions to the vexing question of IPRS and access to drugs in developing nations. In this paper one particular solution, using Open Source model as a potential model for drug discovery is taken up for analysis. The potentials and pitfalls are examined. It is pointed out that Open Source model is relevant for developing nations in developing new drugs. It is suggested that developing nations should give this model a serious consideration and try to use this model in the best possible manner considering their capacity for innovation and as a solution to find cures for neglected and most neglected diseases. It is also pointed out that while Open Source model is not a panacea it is certainly a model worth examining and encouraging.

Keywords: TRIPS, open source, WTO, pharmaceuticals. developing nations, drug research, neglected diseases, access to drugs

Suggested Citation

Srinivas, Krishna Ravi, Trips, Access to Medicines and Developing Nations: Towards an Open Source Solution (November 2006). Available at SSRN: or

Krishna Ravi Srinivas (Contact Author)

Research Information System for Developing Countries (RIS) ( email )

Here is the Coronavirus
related research on SSRN

Paper statistics

Abstract Views
PlumX Metrics